Author of

• 25935

  +

  P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall

  • 26704

    +

    P1.15-36 - A Better Real World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer (ID 13250)

    16:45 - 18:00  |  Author(s): Haiyan Yang
    • Abstract

    Background
    

    To investigate the real world practice of first-line pemetrexed combined with different drugs in patients with advanced Non-squamous non-small cell lung cancer.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    A total number of 164 patients from February 2012 to August 2017 in Hunan Cancer Hospital in the combination of pemetrexed with cisplatin were enrolled in this study. All the patients were divided into 5 groups: PC-P (pemetrexed combined with platinum for 4 cycles and pemetrexed maintenance, arm A), PCA-PA (Pemetrexed plus platinum and bevacizumab 4cycles, pemetrexed combined with bevacizumab maintenance, arm B), PC (pemetrexed combined with platinum chemotherapy 4 cycles, arm C), PCA (pemetrexed with platinum chemotherapy, plus bevacizumab 4 cycles without maintenance, arm D), PC-EGFR TKI (pemetrexed plus platinum chemotherapy 4 cycles, and then EGFR TKI as maintenance treatment, arm E). Efficacy and safety of pemetrexed was performed in each group comparing with each major clinical data.

    4c3880bb027f159e801041b1021e88e8 Result
    

    According to retrospective study , the median PFS for arm A, B, C, D and E were 13 months, 12 months, 5 months, 5 months, 15.8 months respectively; the median OS was 27 month, 21 months, 15 months, 11 months and 31 months respectively. Arm A and Arm C, Arm B and Arm D achieved statistically different on PFS (p<0.05). And Arm A and Arm C, Arm B and Arm D also achieved statistical differences between OS (p<0.05). In the multivariate regression analysis of all patients, we found that the ECOG PS score may be an independent prognostic factor for death from lung cancer patients. Among all the patients, 35 (21.4%) patients presented with non-hematologic serious adverse event (grade 3 and 4). There was no new occurring intolerant adverse event comparing with other clinical trials.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    In this real world study, pemetrexed proved to be high efficacy and well tolerant in advanced NSCLC. The efficiency of maintenance pemetrexed treatment group achieved significantly better outcome than the non-maintenance treatment group. In addition, ECOG PS score may be an independent prognostic factor for the death of patients in lung cancer. There was no new occurring intolerant adverse event comparing with previous clinical trials, the main adverse events in this study were also focused on non-hematologic toxicity. This is consistent with clinical trials.

    6f8b794f3246b0c1e1780bb4d4d5dc53